CEO Gilead responds to Remdesivir patent dispute. How will he protect the patent without getting involved in the dispute?

Gilead CEO responded:? Will protect patents but will not be involved in disputes, patients are preferred. ? In addition, Remdesivir has applied for a global patent right, so there is no problem of patent right. So, Remdesivir is all-matrix, but now the situation is special. The CEO of Gilead knows very well that in order to treat more people, Chuborui Pharmaceutical took more patients back from the hands of death and copied Remdesivir to fight against novel coronavirus, which is strongly supported.

0 1, Borui Medicine responded to the national fight against novel coronavirus and successfully copied Remdesivir.

The whole country is united against novel coronavirus (20 19-nCoV) and is doing its best to get rid of the virus as soon as possible, so that the sick compatriots can get rid of novel coronavirus's torture as soon as possible and let the people of the whole country take off their masks and go out of their homes. This is very good news. Borui Medicine responded to the call of the country to fight against novel coronavirus and successfully copied Redixivir.

However, Remdesivir was first developed by Gilead Company in the United States, and they also applied for a patent. Although? Gilead's research results have not been officially launched, but people all over the world know that Remdesivir belongs to Gilead, so there is a problem of infringement. Everyone is worried about Borui Medicine. After all, it is somebody else's patent. If the patent belongs to China people, there is no problem. Unfortunately, the exclusive right to use Remdesivir is owned by an American company.

02. Gilead CEO responded:? Will protect patents but not get involved in disputes, patients first?

Just when everyone was worried about Borui Medicine, the CEO of Gilead also saw that Wuhan virus announced the use of Redixivir against novel coronavirus. The CEO of Gilead immediately came out and said, we are not considering who the patent belongs to. I also asked my colleagues in charge of patents in the company. Take the patents of other drugs of the company as an example. We have applied for a global patent right for Remdesivir, but there is no patent right. And we will try our best to help patients, and we will protect patent rights, but what we want to say is that patients come first?

This public statement by CEO Gilead shows that he is very aware that Chuborui Pharmaceutical Company copied Remdesivir against novel coronavirus in order to treat more people and take more patients back from death, which strongly supports it. His words:? Will protect patents but not get involved in disputes, patients first? It says it all, Thanksgiving, come on, China! Come on in Wuhan!